New CAR-T therapy aims to tackle tough blood cancers
NCT ID NCT07316907
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 19 times
Summary
This early-stage study is testing a new type of CAR-T cell therapy for people with B-cell blood cancers (like certain leukemias and lymphomas) that have come back or stopped responding to standard treatments. The therapy uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to check if the treatment is safe and to see if it can shrink or control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, 212001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.